Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States
Journal of Medical Economics | August 29, 2016 | Volume: 20 | Issue: 2 | Pages: 140-150
10.1080/13696998.2016.1230123
| PMID 27571538